drugset / Trial / NCT00734032
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.
Timeline
- Start
- 2008-08-26
- Primary completion
- 2009-01-16
- Completion
- 2009-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darapladib | Small molecule | 40 mg | — |
| Subject | Darapladib | Small molecule | 80 mg | — |
| Subject | Darapladib | Small molecule | 160 mg | — |